Eledon Pharmaceuticals(ELDN)
$2.67-0.09 (-3.26%)
ELDN
Eledon Pharmaceuticals financials statements
$2.67
At close:-0.09 (-3.26%)
Want to see ELDN full AI Analyst Report?
Eledon Pharmaceuticals (ELDN) Ratios
1,054 Followers
Eledon Pharmaceuticals Ratios
ELDN's free cash flow for Q2 2026 was $-22.68M. For the 2026 fiscal year, ELDN's free cash flow was increased by $0.00 and operating cash flow was $-22.68M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.40 | 12.42 | 14.41 | 9.19 | 20.07 |
| Quick Ratio | 7.40 | 12.42 | 14.41 | 9.19 | 20.07 |
| Cash Ratio | 1.24 | 1.77 | 1.18 | 8.71 | 19.28 |
| Solvency Ratio | -0.52 | -0.60 | -1.42 | -10.17 | -5.24 |
| Operating Cash Flow Ratio | -3.40 | -4.08 | -10.15 | -4.39 | -6.57 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 47.76M | $ 84.47M | $ -25.73M | $ 50.91M | $ 81.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.05 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.05 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.08 | 1.50 | 12.36 | 1.10 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.02 | 0.02 | 0.05 | 0.05 |
| Net Debt to EBITDA | 0.49 | 0.55 | 0.04 | 0.64 | 2.29 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.08% | 101.21% | 100.00% | 100.00% | 93.61% |
| EBT Per EBIT | 54.75% | 50.66% | 271.02% | 221.13% | 99.98% |
| Return on Assets (ROA) | -26.99% | -20.40% | -130.84% | -94.80% | -20.23% |
| Return on Equity (ROE) | -56.26% | -30.63% | -1616.77% | -104.49% | -21.04% |
| Return on Capital Employed (ROCE) | -55.26% | -42.56% | -50.49% | -46.09% | -22.19% |
| Return on Invested Capital (ROIC) | -55.12% | -42.48% | -50.26% | -45.89% | -20.73% |
| Return on Tangible Assets | -33.39% | -24.95% | -205.61% | -145.62% | -38.55% |
| Earnings Yield | -36.92% | -18.09% | -262.98% | -270.08% | -52.80% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.39 | 0.17 | 0.11 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -943.73 | -2152.82 | -3393.56 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 943.73 | 2152.82 | 3393.56 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.76 | -0.97 | -1.61 | -1.99 | -1.95 |
| Free Cash Flow Per Share | -0.76 | -0.97 | -1.61 | -1.99 | -1.95 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -97.26 | -49.55 | -103.20 | -38.10 | -37.60 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -50.45% | -23.64% | -89.20% | -87.27% | -44.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.70 | -5.49 | -0.38 | -0.37 | -1.89 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.52 | 1.69 | 6.15 | 0.39 | 0.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.98 | -4.23 | -1.12 | -1.15 | -2.26 |
| Price-to-Operating Cash Flow Ratio | -1.98 | -4.23 | -1.12 | -1.15 | -2.26 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | 0.07 | 0.00 | -0.00 | 0.02 |
| Enterprise Value Multiple | -2.24 | -5.10 | -0.35 | 0.26 | 0.51 |
| Enterprise Value | 101.41M | 180.40M | 40.09M | -23.09M | -18.71M |
| EV to EBITDA | -2.24 | -5.10 | -0.35 | 0.26 | 0.51 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.63 | -3.82 | -1.01 | 0.81 | 0.65 |
| EV to Operating Cash Flow | -1.63 | -3.82 | -1.01 | 0.81 | 0.65 |
| Tangible Book Value Per Share | 0.60 | 1.77 | -1.02 | 3.63 | 5.60 |
| Shareholders’ Equity Per Share | 0.99 | 2.43 | 0.29 | 5.89 | 11.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.01 | 0.00 | 0.00 | 0.06 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.56 | -0.75 | -4.73 | -6.16 | -2.33 |
| Tax Burden | 1.00 | 1.01 | 1.00 | 1.00 | 0.94 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.37 | 1.31 | 0.34 | 0.32 | 0.84 |
Currency in USD
